Understanding the progression of Barrett's Esophagus and its risk factors
Official title: A Prospective Study To Define The Role Of Various Factors In Development And Progression Of Gastroesophageal Reflux Disease (GERD) And Barrett's Esophagus And The Creation Of A Registry.
Run by Midwest Veterans' Biomedical Research Foundation · NCT00574327 · Data updated 2026-11-12
This study looks at how certain factors might affect the progression of GERD and Barrett's Esophagus to see who is at higher risk for serious issues like cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Midwest Veterans' Biomedical Research Foundation Academic / other |
| Locations | 1 site (Kansas City, Missouri) |
| Status | Recruiting |
| Started | January 2006 |
| Main results expected | October 2028 |
| Study ends | January 2029 |
| Registry record updated | March 16, 2023 |
| Trial ID | NCT00574327 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients at the Kansas City VA with confirmed Barrett's Esophagus, those with chronic GERD, and individuals with other indicators for endoscopy.
✕Probably not a fit
Patients with uncontrolled significant comorbidities or those unable to provide a medical history may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the risk factors associated with the progression of gastroesophageal reflux disease (GERD) and Barrett's Esophagus (BE), including genetic changes that may lead to esophageal cancer. By systematically collecting data on the natural history of GERD and BE patients, the study seeks to identify those at increased risk for developing dysplasia and adenocarcinoma. The findings could inform decision models for risk stratification and strategies for risk reduction in affected patients.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and surveillance strategies for patients at risk of esophageal cancer.
How similar studies have gone: Other studies have shown success in identifying risk factors for Barrett's Esophagus and esophageal cancer, making this approach both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
All patients must be eligible for care that the Kansas City VA Hospital where this study was approved for enrollment. Inclusion Criteria: * Kansas City VA Patients with confirmed BE with and without dysplasia and patients with reflux disease (patients/cases); patients with other indicators for endoscopy such as anemia, weight loss, diarrhea, but without GERD and PE (controls). Exclusion Criteria: * Patients with uncontrolled significant comorbidities such as cardiovascular, pulmonary, renal, hepatic or metabolic diseases. * Presence of anticoagulation that would increase risk from biopsies * Patients unable to provide history * Patients with dyspepsia
Where it's running
-
Department of Veterans Affairs Medical Center
Kansas City, Missouri, United States Recruiting
Study contacts
- Principal investigator: Prateek Sharma, MD — Department of Veterans Affairs Medical Center of Kansas City
- Study coordinator: April D Higbee, RN, BSN
- Email: april.higbee@va.gov
- Phone: 816-861-4700
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using tissue, brush, and blood tests to improve cancer risk prediction and quality of life tracking in Barrett's Esophagus
This will try extra biopsies, esophageal brushings, blood tests, and short questionnaires to see if they can better predict cancer risk and track quality of life for adults with Barrett's Esophagus who are being evaluated for possible early cancer.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Predictors of symptom improvement after laparoscopic fundoplication
This study tests what preoperative factors help predict which GERD patients will feel better after laparoscopic fundoplication.
-
Thread-Embedding Acupuncture plus a Proton Pump Inhibitor for GERD
This study tests whether adding thread-embedding acupuncture to standard omeprazole treatment helps people with GERD who have a traditional Liver-Stomach constraint-heat pattern.
-
Managing GERD with personalized dietary changes and guided education
A dietary plan and written education are being tested to see if they help adults with chronic GERD reduce symptoms.
-
GERD patient registry study using a large prospective clinical database
A large group of adults with gastroesophageal reflux disease are being looked at in real-world care to see who they are, what treatments they get, and how symptoms and well-being change after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.